AP NEWS

Boston Heart Diagnostics Announces New Scientific Advisory Board Appointments

September 18, 2018

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Sep 18, 2018--Boston Heart Diagnostics, one of the leading disease management laboratories in the United States, is pleased to announce the company’s newly-appointed scientific advisory board.

Boston Heart Diagnostics’ 2018 Scientific Advisory Board is comprised of recognized experts in their respective medical fields. Boston Heart Diagnostics’ Scientific Advisory Board includes:

Sam Tsimikas, MD, FACC, University of California, San Diego, specializing in Lp(a) Michael Davidson, MD, FACC, University of Chicago, specializing in Omega-3 Fatty Acids Peter Reaven, MD, University of Arizona, specializing in Diabetes and Insulin Resistance Dennis Goodman, MD, FACC, New York University, specializing in Integrative Medicine H. Robert Superko, MD, FACC, FAHA, Cholesterol, Genetics, and Heart Disease Institute, specializing in LDL & HDL Subclass

Each member contributes to the scientific advisory board via their respective medical fields and addresses the clinical utility of advanced laboratory testing.

“Our scientific advisory board is a pivotal addition to our team that allows Boston Heart to continue to stay on the cutting edge of identifying hidden cardiovascular disease risks and improving patient care,” stated Pat Noland, President, Boston Heart Diagnostics. “They are all leaders in their fields and we are looking forward to collaborating with them moving forward.”

Sam Tsimikas, MD, FACC

Dr. Tsimikas, a cardiologist, is an expert on Lipoprotein(a) (Lp(a)). Tsimikas is the lead author of the 2018 American College of Cardiology and American Heart Association position paper on the clinical utility of measuring Lp(a). Boston Heart offers the Lp(a) test as it is a predictor of heart disease risk and helps to explain heart disease in patients with “normal” blood cholesterol. Tsimikas’ expertise in this area will help to get Lp(a) accepted as a “standard of care” for lipid and heart disease risk testing.

Michael Davidson, MD, FACC

Dr. Davidson, a cardiologist, is an expert in omega-3 fatty acid metabolism and clinical use. Dr. Davidson is the co-author of the National Lipid Association’s (NLA) position statements, co-author of the 2011 NLA Expert Lipid Consensus document, and is involved in large omega-3 clinical trials. Omega-3 fatty acids can decrease triglycerides and lower the risk for heart disease or stroke. The Boston Heart Fatty Acid Balance TM Test measure all the major fatty acids, including omega-3s. His expertise will continue to support the clinical relevance for testing fatty acids.

Peter Reaven, MD

Dr. Reaven is an international expert and researcher on insulin resistance and diabetes and has participated in many of the large diabetes treatment trials. The presence of insulin resistance can indicate a high risk of developing heart disease or type 2 diabetes. Dr. Reaven supports use of appropriate testing to help identify individuals who could be part of the large, insulin resistant patient population.

Dennis Goodman, MD, FACC

Dr. Goodman is a cardiologist and an expert in integrative medicine. Dr. Goodman supports advanced testing as he believes it can be useful in identifying patients who are most likely to benefit from integrative therapies such as the use of folic acid, vitamin D, magnesium, citrus bergamot and polyphenols. Dr. Goodman specializes in patients who are intolerant of statins and utilizes Boston Heart Testing to assist with the selection of natural alternatives. He provides support for the clinical utility of Boston Heart testing, and how it fits into the integrative medicine field.

H. Robert Superko, MD, FACC, FAHA

Dr. Superko was the founder of Berkeley Heart Lab in 1996, and is an international expert on lipoprotein subfractionization. Dr. Superko has published numerous articles supporting the clinical utility of advanced lipid tests and how they can help characterize a patient’s disease risk and provide individualized treatments. His support of the clinical use of Boston Heart’s LDL and HDL subfraction testing will help healthcare providers understand the appropriate clinical use of advanced testing.

Boston Heart Diagnostics’ Scientific Advisory Board provides insight and develops recommendations regarding the clinical utility of advanced testing.

For more information on the tests and programs available to help change the course of cardiovascular and related diseases, visit www.BostonHeartDiagnostics.com.

About Boston Heart

Boston Heart Diagnostics, a subsidiary of Eurofins Scientific (EUFI.PA), is transforming the treatment of cardiovascular disease by providing healthcare providers and their patients with novel, personalized diagnostics and integrated customized lifestyle programs that have the power to change the way clinicians and patients communicate about disease and improve heart health. Boston Heart looks beyond the “good” and “bad” cholesterol assessment that conventional labs provide to give a more complete picture of heart health. Founded by renowned cardiovascular researchers and led by seasoned lab and diagnostic executives, Boston Heart is one of the fastest growing health companies in the country. For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005246/en/

CONTACT: Weber Shandwick

Kelly Vesty, 617-520-7061

kvesty@webershandwick.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH CARDIOLOGY FITNESS & NUTRITION RESEARCH DIABETES SCIENCE GENERAL HEALTH

SOURCE: Boston Heart Diagnostics

Copyright Business Wire 2018.

PUB: 09/18/2018 09:08 AM/DISC: 09/18/2018 09:08 AM

http://www.businesswire.com/news/home/20180918005246/en

AP RADIO
Update hourly